Clinical Trials on Peritoneal Carcinomatosis in United States

Total 885 results

University of Washington
National Cancer Institute (NCI)

Terminated

The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors

Ovarian Cancer | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Adenocarcinoma | Ovarian... and other conditions

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Terminated

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
The University of Texas Health Science Center at...

Completed

A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer (ONTAK)

Epithelial Ovarian Cancer | Fallopian Tube Carcinoma | Extraovarian Peritoneal Cancer

United States
Women and Infants Hospital of Rhode Island
Amgen

Terminated

Panitumumab and Gemcitabine in Relapsed Ovarian Cancer (PanGem)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
London North West Healthcare NHS Trust
Imperial College Healthcare NHS Trust

Not yet recruiting

Consequences of Obstetric Anal Sphincter Injuries on Maternal Psychology and Relationship Experience (COMPaRE)

Mental Health Impairment | Obstetric Complication | Incontinence | Perineal Tear | Obstetric Trauma | Relation, Mother-Child | Relation, Family

United Kingdom
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Critical Outcome Technologies Inc.
M.D. Anderson Cancer Center; Northwestern Memorial Hospital

Unknown

Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101)

Cervical Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Fallopian Tube Cancer | Lung Cancer | Endometrial Cancer | Peritoneal Cancer | HNSCC

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Progressive Disease | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | High Grade Ovarian... and other conditions

United States
Arjun Mittra
National Cancer Institute (NCI)

Recruiting

Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer

Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Peritoneum

United States
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University; Rutgers University

Completed

Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Benaroya Research Institute
GlaxoSmithKline; Genentech, Inc.

Completed

Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
National Cancer Institute (NCI)

Completed

Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
National Cancer Institute (NCI)

Completed

Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Dana-Farber Cancer Institute

Withdrawn

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
NYU Langone Health
National Cancer Institute (NCI)

Completed

Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Shattuck Labs, Inc.

Active, not recruiting

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma

United States, United Kingdom, Spain, Canada
Tracon Pharmaceuticals Inc.

Completed

Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Recurrent Ovarian Cancer

United States
Arsenal Biosciences, Inc.

Recruiting

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Neoplasms, Glandular and Epithelial | Recurrence | Ovarian Diseases | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Carcinoma, Ovarian Epithelial | Abdominal Neoplasm | Genital Neoplasm, Female

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Clovis Oncology, Inc.

Active, not recruiting

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
M.D. Anderson Cancer Center
The Blanton Davis Ovarian Cancer Research Program

Unknown

Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
David O'Malley
Genentech, Inc.

Unknown

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | No Prior Chemotherapy

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Dr Tim Exell
Portsmouth Hospitals NHS Trust; Solent NHS Trust

Recruiting

Comparison of Gait in Different Support Conditions for Foot Drop

Foot Drop, Unspecified Foot

United Kingdom
MEI Pharma, Inc.

Completed

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer (OVATURE)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States, Spain, Belgium, United Kingdom, Australia, Italy, Poland
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Mucinous... and other conditions

United States, Korea, Republic of, Japan
NextStep Robotics Inc.

Recruiting

Ankle Robotics After Stroke

Stroke | Hemiparesis | Foot Drop

United States
NextStep Robotics Inc.
University of Maryland, Baltimore

Withdrawn

TREAT Foot Drop After Stroke With Ankle Robot (TREAT)

Stroke | Hemiparesis | Foot Drop

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
Texas Woman's University
Baylor Research Institute

Completed

Effects of Two Different Types of Ankle Foot Orthoses on Gait Outcomes in Patients With Subacute Stroke.

Stroke | Hemiplegia | Hemiparesis | Foot Drop | CVA

United States
The University of Texas Health Science Center at...

Terminated

A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer

Epithelial Ovarian Cancer | Fallopian Tube Carcinoma | Extraovarian Peritoneal Cancer

United States
Oncolix, Inc.

Unknown

Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer (ProlantaOC)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Washington University School of Medicine

Completed

Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients

Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Invasive Epithelial Ovarian Cancer

United States
University of Arizona
National Cancer Institute (NCI)

Completed

Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Roswell Park Cancer Institute
AstraZeneca

Active, not recruiting

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Serous Adenocarcinoma

United States
M.D. Anderson Cancer Center

Completed

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer

Sarcoma | Adenocarcinoma | Gastrointestinal Neoplasms | Ovarian Neoplasms | Peritoneal Neoplasms | Neuroblastoma | Rhabdomyosarcoma | Wilms Tumor | Adrenocortical Carcinoma | Desmoplastic Small Round Cell Tumor | Retroperitoneal Neoplasms

United States
Kadmon Corporation, LLC

Completed

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Non-Small Cell Lung Cancer | Brain Metastases | Leptomeningeal Metastases

United States
University of California, Davis
National Cancer Institute (NCI); Amino Up Chemicals Co., Ltd.

Recruiting

Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy

Fallopian Tube Carcinoma | Peritoneal Carcinoma | Ovarian Epithelial Carcinoma

United States
Dana-Farber Cancer Institute
National Institute of Nursing Research (NINR)

Withdrawn

SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care (SIGNAL)

Cervical Cancer | Gynecologic Cancer | Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Uterine Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
University of Colorado, Denver
ImmunoGen, Inc.

Recruiting

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Fallopian Tube Cancer | Peritoneal Cancer | Ovary Cancer

United States
Southern Illinois University

Completed

Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States

Clinical Trials on Peritoneal Carcinomatosis in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations